

Status: Currently Official on 15-Feb-2025
Official Date: Official as of 01-May-2019
Document Type: USP Monographs
DocId: GUID-22FDDAB1-1FA1-453B-8E2E-69031D3DB8C8_2_en-US
DOI: https://doi.org/10.31003/USPNF_M36047_02_01
DOI Ref: f12iz

© 2025 USPC
Do not distribute

Guanabenz Acetate Tablets

DEFINITION

Change to read:

Guanabenz Acetate Tablets contain ▲an amount of guanabenz acetate equivalent to▲ (USP 1-May-2019) NLT 90.0% and NMT 110.0% of the labeled amount of guanabenz ($C_8H_8N_4Cl_2$).

IDENTIFICATION

• A.

Sample: Transfer an amount of powdered Tablets, equivalent to 8 mg of guanabenz, to a 60-mL separator. Add 10 mL of 0.1 N [hydrochloric acid](#), and shake to disperse the powder. Shake the mixture with three 10-mL portions of [chloroform](#), discarding the chloroform phase each time. Add 5 mL of 1 N [sodium hydroxide](#), and extract with two 25-mL portions of [ether](#), filtering the ether extracts. Evaporate the combined extracts to dryness with the aid of a current of air.

Acceptance criteria: The IR absorption spectrum of a potassium bromide dispersion of the *Sample* exhibits maxima at the same wavelengths as those of a similar preparation of [USP Guanabenz Acetate RS](#).

Add the following:

▲• B. The retention time of the major peak of the *Sample solution* corresponds to that of the *Standard solution*, as obtained in the Assay.▲ (USP 1-May-2019)

ASSAY

Change to read:

• PROCEDURE

Mobile phase: [Methanol](#), [phosphoric acid](#), and [water](#) (430:3:570)

Diluent: Dissolve 8.2 g of [sodium acetate](#) in 20 mL of [water](#), add 5.7 mL of glacial [acetic acid](#), and dilute with [methanol](#) to 1 L.

System suitability solution: Transfer 30 mg of guanabenz acetate to a 100-mL stoppered flask. Add about 50 mL of 0.1 N [hydrochloric acid](#), heat on a steam bath for 60 min, and allow the solution to cool.

Standard solution: 0.1 mg/mL of [USP Guanabenz Acetate RS](#) in *Diluent* prepared as follows. Transfer a suitable amount of [USP Guanabenz Acetate RS](#) to a suitable volumetric flask. Add 10% of the total volume of [water](#), shake to dissolve the solids, and dilute with *Diluent* to volume.

Sample solution: Nominally 0.08 mg/mL of guanabenz prepared as follows. Transfer 10 Tablets to a 500-mL volumetric flask. Add 50 mL of [water](#), stir by mechanical means until the solids are well dispersed, add 400 mL of *Diluent*, and stir for 45 min. Dilute with *Diluent* to volume, and centrifuge a portion of the mixture until a clear supernatant is obtained. If necessary, dilute a portion of the supernatant quantitatively with a mixture of *Diluent* and water (90:10).

Chromatographic system

(See [Chromatography \(621\)](#), [System Suitability](#).)

Mode: LC

Detector: UV 245 nm

Column: ▲3.9-mm▲ (USP 1-May-2019) × 30-cm; ▲10-μm▲ (USP 1-May-2019) packing [L1](#)

Flow rate: 2 mL/min

Injection volume: 20 μL

▲**Run time:** NLT 6 times the retention time of the guanabenz peak▲ (USP 1-May-2019)

System suitability

Samples: *System suitability solution* and *Standard solution*

Suitability requirements

Resolution: NLT 1.6 between guanabenz and the peak eluting before it, *System suitability solution*

Relative standard deviation: NMT 2.0%, Standard solution

Analysis**Samples:** *Standard solution* and *Sample solution*Calculate the percentage of the labeled amount of guanabenz ($C_8H_8N_4Cl_2$) in the portion of Tablets taken:

$$\text{Result} = (r_U/r_S) \times (C_S/C_U) \times (M_{r1}/M_{r2}) \times 100$$

 r_U = peak response from the *Sample solution* r_S = peak response from the *Standard solution* C_S = concentration of [USP Guanabenz Acetate RS](#) in the *Standard solution* (mg/mL) C_U = nominal concentration of guanabenz in the *Sample solution* (mg/mL) M_{r1} = molecular weight of guanabenz, 231.08 M_{r2} = molecular weight of guanabenz acetate, 291.13**Acceptance criteria:** 90.0%–110.0%**PERFORMANCE TESTS**• [DISSOLUTION \(711\)](#)**Medium:** Water; 1000 mL**Apparatus 2:** 50 rpm**Time:** 60 min**Standard solution:** A known concentration of [USP Guanabenz Acetate RS](#) in *Medium***Sample solution:** Pass a portion of the solution under test through a suitable filter, and dilute with *Medium* to a concentration similar to that of the *Standard solution*.**Instrumental conditions****Mode:** UV-Vis**Analytical wavelength:** Maximum absorbance at about 272 nm**Analysis****Samples:** *Standard solution* and *Sample solution*Determine the percentage of the labeled amount of guanabenz ($C_8H_8N_4Cl_2$) dissolved.**Tolerances:** NLT 75% (Q) of the labeled amount of guanabenz ($C_8H_8N_4Cl_2$) is dissolved.• [UNIFORMITY OF DOSAGE UNITS \(905\)](#): Meet the requirements**IMPURITIES**• **ORGANIC IMPURITIES****Mobile phase, Diluent, System suitability solution, Sample solution, Chromatographic system, and System suitability:** Proceed as directed in the Assay.**Standard solution:** Dilute 2 mL of the *Standard solution* from the Assay with *Diluent* to 100 mL.**Analysis****Samples:** *Sample solution* and *Standard solution*Calculate the percentage of any impurity observed having a relative retention time corresponding to the component eluting before guanabenz from the *System suitability solution*.**Acceptance criteria:** NMT 2%**ADDITIONAL REQUIREMENTS**• **PACKAGING AND STORAGE:** Preserve in tight, light-resistant containers.• [USP REFERENCE STANDARDS \(11\)](#)[USP Guanabenz Acetate RS](#)

Topic/Question	Contact	Expert Committee
GUANABENZ ACETATE TABLETS	Documentary Standards Support	SM22020 Small Molecules 2

Chromatographic Database Information: [Chromatographic Database](#)

Most Recently Appeared In:
Pharmacopeial Forum: Volume No. PF 43(5)

Current DocID: GUID-22FDDAB1-1FA1-453B-8E2E-69031D3DB8C8_2_en-US

DOI: https://doi.org/10.31003/USPNF_M36047_02_01

DOI ref: [f12iz](#)

OFFICIAL